Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens

Trial Profile

Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 26 Mar 2018 Last checked against European Clinical Trials Database record.
    • 24 Mar 2018 Status changed from suspended to discontinued.
    • 09 Sep 2017 Results (n=13) presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top